2025-03-31 18:35:18
Latest Post
NHPC commissions 3 units of Parbati-II HE project
ixigo announces APRIL FULL REFUND SALE for 1st April - 100 Lucky Travellers To Win 100% Refund on Flight Bookings
Engineers India Ltd receives orders worth Rs. 245 crores
Blue Star appoints Mohit Sud as Group President, Unitary Cooling Products 
Jyoti Ltd receives Rs. 108.17 crores IT demand notice for AY 2020-21
Stock Report
Jenburkt Pharmaceuticals Ltd Q4 FY2022 PAT at Rs. 3.44 crore
Posted On : 2022-05-28 15:21:57( TIMEZONE : IST )
JENBURKT PHARMACEUTICALS LTD. has reported Standalone financial results for the period ended March 31, 2022.
Financial Results (Q4 FY2022) - QoQ Comparison
The company has reported total income of Rs. 29.5683 crores during the period ended March 31, 2022 as compared to Rs. 34.2871 crores during the period ended December 31, 2021.
The company has posted net profit / (loss) of Rs. 3.4488 crores for the period ended March 31, 2022 as against net profit / (loss) of Rs. 6.2271 crores for the period ended December 31, 2021.
The company has reported EPS of Rs. 7.51 for the period ended March 31, 2022 as compared to Rs. 13.57 for the period ended December 31, 2021.
| Financials | Q4 FY2022 | Q3 FY2022 | % Change |
| Total Income | ₹ 29.5683 crs | ₹34.2871 crs |  -13.76% |
| Net Profit | ₹3.4488 crs | ₹6.2271 crs | -44.62% |
| EPS | ₹7.51 | ₹13.57 | -44.66% |
Financial Results (Q4 FY2022) - YoY Comparison
The company has reported total income of Rs. 29.5683 crores during the period ended March 31, 2022 as compared to Rs.30.8193 crores during the period ended March 31, 2021.
The company has posted net profit / (loss) of Rs.3.4488 crores for the period ended March 31, 2022 as against net profit / (loss) of Rs.3.8767 crores for the period ended March 31, 2021.
The company has reported EPS of Rs.7.51 for the period ended March 31, 2022 as compared to Rs.8.45 for the period ended March 31, 2021.
| Financials | Q4 FY2022 | Q4 FY2021 | % Change |
| Total Income | ₹ 29.5683 crs | ₹30.8193 crs | -4.06% |
| Net Profit | ₹3.4488 crs | ₹3.8767 crs | -11.04% |
| EPS | ₹7.51 | ₹8.45 | -11.12% |
Financial Results (Year Ended FY2022) - YoY Comparison
The company has reported total income of Rs.128.9291 crores during the Financial Year ended March 31, 2022 as compared to Rs.113.6027 crores during the Financial Year ended March 31, 2021.
The company has posted net profit / (loss) of Rs.22.2972 crores for the Financial Year ended March 31, 2022 as against net profit / (loss) of Rs.16.5024 crores for the Financial Year ended March 31, 2021.
The company has reported EPS of Rs.48.58 for the Financial Year ended March 31, 2022 as compared to Rs.35.96 for the Financial Year ended March 31, 2021.
| Financials | Year Ended FY2022 | Year Ended FY2021 | % Change |
| Total Income | ₹128.9291 crs | ₹113.6027 crs |  13.49% |
| Net Profit | ₹22.2972 crs | ₹16.5024 crs | 35.11% |
| EPS | ₹48.58 | ₹35.96 | 35.09% |
Shares of JENBURKT PHARMACEUTICALS LTD. was last trading in BSE at Rs. 544.15 as compared to the previous close of Rs. 562.80. The total number of shares traded during the day was 1191 in over 51 trades.
The stock hit an intraday high of Rs. 555.00 and intraday low of 536.25. The net turnover during the day was Rs. 651111.00.
